Common Cold
Conditions
Keywords
common cold, treatment, inflammatory symptoms of superior air passages affection
Brief summary
The primary outcome of this study is to evaluate the clinical efficacy of the dose fixed combination and each drug, that composes it, isolated, regarding the respiratory symptoms improvement in superior air passages acute affection in children between 2 and 6 years old.
Interventions
DRUGBronpheniramine and fenilefrine (Decongex Plus)
Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
DRUGBronpheniramine isolated
Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
DRUGFenilefrine isolated
Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
Sponsors
Ache Laboratorios Farmaceuticos S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
2 Years to 6 Years
Healthy volunteers
No
Inclusion criteria
1. Patients between 2 and 6 years old, according to dosage information provided in the product package insert. 2. Patient with a relative available for observation of symptoms during the night. 3. Patients with acute symptoms of air passages jeopardizing, initiated, at least, 24 hours before patient inclusion in this protocol and, at most, in the 3 days before patient inclusion. 4. Patients facing at least a 7 points score in the addition of general symptoms (rhinorrhea, sneeze, itching, nose obstruction and coughing). 5. At least two symptoms must be moderated in scale, for specific evaluation. 6. Presence of fluid and/or sputum verified through a rhinoscopy.
Exclusion criteria
1. Children younger than 2 years old or a weight and/or height percentual inferior to 10. 2. Children with corporal weight superior to 30Kg. 3. Suggestive signs of superior air passages bacterial infection to the rhinoscopy, otoscopy and oropharingoscopy. 4. Chronic oral breath with a 6 months history. 5. Presence of degree II and III of nasal septal deviation (in any region and in any nasal fossa) and/or presence of nasal polyp or other conditions that determine nasal obstruction. 6. Patients in a chronic medication treatment for allergy. 7. Patients with an asthma clinical history confirmed (diagnosed). 8. Personal preceding of nasal surgery that in the opinion of the investigator can influence in the resistance to the air nose flow. 9. Children older than 5 years old that are not registered in the school. 10. Children that don´t have vaccination notebook. 11. Patient that had used prohibited medication, during the established period before V0 - Randomization Visit (See Picture 1). 12. Hypersensitive history to the study drug or its components. 13. Patient that have participated in, during the last 12 months, study protocols (according to Resolution 251, dated of August, 7th 1997, item III, sub-item J, Investigator Responsibility, its recommended that the same person does not be subject of a clinical study in a new project before have elapsed 1(one) year from previous study participation, unless there is a direct benefit to the study patient). 14. Relatives of sponsor´s or study site´s employee. 15. Patients with gastroesofagic reflux disease. 16. Presence of psychiatry diseases. 17. Presence of mental disorder of any etiology. 18. Renal and hepatic insufficiency. 19. Patient with current evidence of clinically significant diseases, of origin: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrinological, psychiatric, self immune, pulmonary, or other that preclude, according to the investigator criteria, the subject participation. 20. Patients with genetic diseases. 21. Any finding of clinical observation (anamneses and physical evaluation) that be understood by the investigator as risk to the patient participation in the study. 22. Any finding of lab result that the investigator judges as a risk to the patient, considering the participation in the study. 23. Patients with AST and ALT levels higher than 20% related to the upper normal limits; total bilirubins with an increase of 10% related to the upper normal limits; fasting serum/blood glucose \>99mg/dl or postprandial serum/blood glucose \>140mg/dl; Hb \<10g/dl ou Hb \>15 g/dl; serum creatinine with levels over than 10% of upper limit; serum potassium under 3,5 mEq/L, or upper 5,1 mEq/L; serum sodium under 136 mEq/L, or upper 145 mEq/L. 24. Presence of hematogenous or meliceric, purulent or mucus purulent secretion, bulging or malformation (leporine lips and nasolabial fissure surgically corrected or not) in the region of the nasal vestibule.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the clinical efficacy of the dose fixed combination and each drug, that compose it, isolated, regarding the respiratory symptoms improvement in superior air passages acute affection in children between 2 and 6 years old. | 04/2010 |
Secondary
| Measure | Time frame |
|---|---|
| Patient adherence to the treatment. | 04/2010 |
| Use of co intervention for symptom relief during treatment | Assessed during the treatment in the diary and questioned by the Investigator at the visits |
| Evaluate the intensity of the symptoms during the treatment | Assessed during the treatment |
| Adverse effect appearance during the study and tolerability | Assessed during the treatment and at the final visit |
Countries
Brazil
Outcome results
None listed